StockStory Backs UnitedHealth at $384.7 Billion, Flags STERIS and Agilent as Sells
Updated
Updated · stockstory.org · Jul 24
StockStory Backs UnitedHealth at $384.7 Billion, Flags STERIS and Agilent as Sells
2 articles · Updated · stockstory.org · Jul 24
Summary
UnitedHealth was singled out as the healthcare stock to watch, while StockStory advised investors to avoid STERIS and Agilent despite the sector’s recent gains.
9.7% healthcare stock returns over the past six months beat the S&P 500 by 1.8 percentage points, but the report said heavy regulation still makes stock selection critical.
UnitedHealth’s appeal centered on 10.6% annual revenue growth over five years, a $450.1 billion revenue base, and stronger returns on capital; the stock trades at 20.3x forward earnings.
STERIS and Agilent were marked down for slower growth—7.5% and 4.5% annualized, respectively—along with weak efficiency or fading returns on capital, even as they trade at 18.9x and 21.1x forward P/E.
Why are analysts ignoring the massive 2026 earnings turnarounds for Agilent and STERIS while continuing to praise UnitedHealth?
Are backward-looking financial metrics blinding investors to the true growth potential of essential medical sterilization and lab technology companies?
Could hidden regulatory risks in the healthcare sector turn today's top-performing insurance giants into tomorrow's biggest market losers?